“The mRNA story has just begun. To cope with the rising demand for vaccines worldwide, the company proactively ventured to invest in expanding its mRNA vaccine production facility,” Yoo wrote. “For COVID-19 mRNA vaccines in the market, production of mRNA drug substance, encapsulated [lipid nanoparticle] final product, and fill/finish activities have often been conducted at different sites, increasing the risk of contamination, time, and cost. Samsung Biologics’ mRNA facility provides end-to-end solutions from pDNA linearization to fill/finish, all under one roof.”
https://www.getholistichealth.com/120490/as-mrna-vaccine-production-expectations-increase-samsung-biologics-invests-in-end-to-end-expertise/
#mRNA #mRNAVaccines #SamsungBiologics #mRNATechnology #Generictechnology #Genetherapy
https://www.getholistichealth.com/120490/as-mrna-vaccine-production-expectations-increase-samsung-biologics-invests-in-end-to-end-expertise/
#mRNA #mRNAVaccines #SamsungBiologics #mRNATechnology #Generictechnology #Genetherapy
Getholistichealth
As mRNA Vaccine Production Expectations Increase, Samsung Biologics Invests in End-to-End Expertise
The use of mRNA vaccines to prevent COVID-19 infections was a turning point for the research and development of mRNA technology. COVID-19 vaccines produced by Moderna and Pfizer were the first mRNA vaccines approved for human use, and their demonstrated effectiveness…